COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

As of 12:32:25 pm GMT+2. Market open. (Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most ...

COMPASS Pathways plc (CMPS) has filed for up to 40,089,163 share offering by selling stockholders.

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-0.38 EPS, expectations were $-0.37. Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. We recently ...

A look at the shareholders of COMPASS Pathways plc (NASDAQ:CMPS) can tell us which group is most powerful. The group holding the most number of shares in the company, around 32% to be precise, is ...